Drugs / Cu-NU101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07635524 | Aug 2026 → Aug 2028 expected | prostate cancer | Hoag Memorial Hospital Presbyterian | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cu-NU101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07635524 ↗ |
| Modality | Diagnostic / imaging agent | “new investigational Molecular Imaging (MI) agent called 61Cu-NU101” NCT07635524 ↗ |
| Route | Intravenous | “administered as a slow intravenous bolus over 10 seconds” NCT07635524 ↗ |